GlobeNewswire (Mon, 4:30PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
498 people get SUPN articles and Market Currents by email alert.
Get email alerts on SUPN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (May 6, 2013)
-
-
GlobeNewswire (Apr 26, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
-
-
-
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 1, 2013)
-
-
-
GlobeNewswire (Jan 14, 2013)
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
ACRX Falls On Financing, Creating Opportunity Ahead Of Phase III DataPropThink • Thu, Dec 6, 2012 -
-
-
-
-
-
-
-
-
2012 Biotech IPOs: Age Of The Dreamers?Bioassociate Consulting • Wed, Jul 4, 2012 -
-
-
-
-
GlobeNewswire (Mon, 4:30PM)
-
GlobeNewswire (May 13, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (Apr 26, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 1, 2013)
-
GlobeNewswire (Jan 14, 2013)
-
GlobeNewswire (Nov 29, 2012)
-
GlobeNewswire (Nov 20, 2012)
-
GlobeNewswire (Nov 19, 2012)
-
GlobeNewswire (Nov 7, 2012)
-
GlobeNewswire (Nov 5, 2012)
-
GlobeNewswire (Oct 31, 2012)
-
GlobeNewswire (Oct 22, 2012)
-
GlobeNewswire (Aug 29, 2012)
-
GlobeNewswire (Aug 10, 2012)
-
GlobeNewswire (Jul 20, 2012)
SUPN vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. Our extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization,... More
-
Chemistfrog
$SUPN I believe entry down here is wise. Q1 financials could really give the company momo.. Final approval for Trokendi in June/July - View all 2 replies
-
joe kelly: You have any opinion on cytk? Keeps coming up on my radar along with supn. -
Chemistfrog: $CYTK chart is in breakout mode. Many catalysts ahead for 13. Watch earnings release for phase IIb update.. I like the company. Good future.
-
- View all 1 replies
-
-
- View all 0 replies
-
freefdawatchlist
http://bit.ly/MAjrXs Premarket gainer $ENTR (23%), $AMRN(11.32%), $SUPN(8%), $PWRD(5%) - View all 0 replies
LATEST REPLIES
-
Chemistfrog
$SUPN I believe entry down here is wise. Q1 financials could really give the company momo.. Final approval for Trokendi in June/July - View all 2 replies
-
joe kelly: You have any opinion on cytk? Keeps coming up on my radar along with supn.
-
Chemistfrog: $CYTK chart is in breakout mode. Many catalysts ahead for 13. Watch earnings release for phase IIb update.. I like the company. Good future.
-
- View all 1 replies
-